Y Lan Truong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Y Lan Truong has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Bahgat Gerges
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center
8 shared publications - Issam Raad
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8 shared publications - Joel Rosenblatt
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center
8 shared publications - Ray Hachem
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications - Ying Jiang
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications - Anne-Marie Chaftari
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (6) , e0192025
Antimicrobial elution patterns correlate with antibacterial and antifungal activities of three antimicrobial central venous catheters in serum
Antimicrobial central venous catheters (CVCs) help prevent CVC-related bloodstream infection (CRBSI), and their effectiveness depends on sustaining broad antimicrobial activity in serum. A new CVC containing minocycline, rifampin, and chlorhexidine (MRC) was recently approved, complementing existing minocycline-rifampin (MR) and chlorhexidine-silver-sulfadiazine (CSiSz) CVCs. This study compared the elution profiles of minocycline, rifampin, and chlorhexidine from these three CVC types in serum and assessed resulting antimicrobial durability against CRBSI pathogens. MRCs were prepared by impregnation with minocycline and rifampin, followed by sequential chlorhexidine coating; commercial MR and CSiSz CVCs served as comparators. CVCs were immersed in plasma for 24 h, and then in serum for 3 weeks. At baseline and weekly intervals, CVC segments were analyzed for antimicrobial content and challenged with clinical CRBSI isolates. MRC retained higher minocycline and rifampin levels than MR and higher chlorhexidine levels than CSiSz after 3 weeks in serum. Correspondingly, MRC demonstrated superior inhibition of gram-negative colonization ( Klebsiella pneumoniae , Escherichia coli , Acinetobacter baumannii ) and Enterococcus faecalis at week 3 ( P ≤ 0.028). They also showed greater activity against Candida species (spp.) ( C. albicans , C. glabrata ) at weeks 2 and 3 ( P ≤ 0.005). MR and MRC CVCs completely prevented methicillin-resistant Staphylococcus aureus and S. epidermidis colonization for 3 weeks, outperforming CSiSz ( P = 0.003). In conclusion, slow elution from MRC CVCs resulted in significantly enhanced antimicrobial durability against gram-negative bacteria, E. faecalis , and Candida spp. MR and MRC CVCs provided equivalent, sustained protection against Staphylococcal colonization, both surpassing CSiSz CVCs.
- 3 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (6) , e0192025
Open AccessAntimicrobial elution patterns correlate with antibacterial and antifungal activities of three antimicrobial central venous catheters in serum
Antimicrobial central venous catheters (CVCs) help prevent CVC-related bloodstream infection (CRBSI), and their effectiveness depends on sustaining broad antimicrobial activity in serum. A new CVC containing minocycline, rifampin, and chlorhexidine (MRC) was recently approved, complementing existing minocycline-rifampin (MR) and chlorhexidine-silver-sulfadiazine (CSiSz) CVCs. This study compared the elution profiles of minocycline, rifampin, and chlorhexidine from these three CVC types in serum and assessed resulting antimicrobial durability against CRBSI pathogens. MRCs were prepared by impregnation with minocycline and rifampin, followed by sequential chlorhexidine coating; commercial MR and CSiSz CVCs served as comparators. CVCs were immersed in plasma for 24 h, and then in serum for 3 weeks. At baseline and weekly intervals, CVC segments were analyzed for antimicrobial content and challenged with clinical CRBSI isolates. MRC retained higher minocycline and rifampin levels than MR and higher chlorhexidine levels than CSiSz after 3 weeks in serum. Correspondingly, MRC demonstrated superior inhibition of gram-negative colonization ( Klebsiella pneumoniae , Escherichia coli , Acinetobacter baumannii ) and Enterococcus faecalis at week 3 ( P ≤ 0.028). They also showed greater activity against Candida species (spp.) ( C. albicans , C. glabrata ) at weeks 2 and 3 ( P ≤ 0.005). MR and MRC CVCs completely prevented methicillin-resistant Staphylococcus aureus and S. epidermidis colonization for 3 weeks, outperforming CSiSz ( P = 0.003). In conclusion, slow elution from MRC CVCs resulted in significantly enhanced antimicrobial durability against gram-negative bacteria, E. faecalis , and Candida spp. MR and MRC CVCs provided equivalent, sustained protection against Staphylococcal colonization, both surpassing CSiSz CVCs.
- Open Access
Elevated Antibacterial Activity of a Polygalacturonic + Caprylic Acids Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model
Bacterial biofilms play a major role in delayed wound-healing and in the development of chronic, non-healing wounds. Natural, plant-based agents, which can eradicate bacterial biofilms, are alternatives to antibiotics and antiseptics in the treatment of bacterially contaminated wounds. Bacterial wound biofilms are three-dimensional and complex microbial communities. Therefore, in this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to compare a commonly used natural agent in wound care, hypochlorous acid (HOCl), to a combination of two natural plant-based agents, polygalacturonic acid (PG) and caprylic acid (CAP) (PG + CAP), for their abilities to eradicate resistant bacterial biofilms of common wound pathogens methicillin resistant Staphylococcus aureus (MRSA), multi-drug resistant (MDR) Pseudomonas aeruginosa, metallo β-Lactamase Escherichia coli, and Streptococcus pyogenes. PG + CAP produced a significantly greater reduction in viable organisms when compared to HOCL (p ≤ 0.05) against all tested bacterial isolates. PG + CAP was highly effective against biofilms of all resistant bacterial isolates and is a promising option that merits further study for treating chronic wounds contaminated with bacterial biofilms.
Open AccessElevated Antibacterial Activity of a Polygalacturonic + Caprylic Acids Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model
Bacterial biofilms play a major role in delayed wound-healing and in the development of chronic, non-healing wounds. Natural, plant-based agents, which can eradicate bacterial biofilms, are alternatives to antibiotics and antiseptics in the treatment of bacterially contaminated wounds. Bacterial wound biofilms are three-dimensional and complex microbial communities. Therefore, in this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to compare a commonly used natural agent in wound care, hypochlorous acid (HOCl), to a combination of two natural plant-based agents, polygalacturonic acid (PG) and caprylic acid (CAP) (PG + CAP), for their abilities to eradicate resistant bacterial biofilms of common wound pathogens methicillin resistant Staphylococcus aureus (MRSA), multi-drug resistant (MDR) Pseudomonas aeruginosa, metallo β-Lactamase Escherichia coli, and Streptococcus pyogenes. PG + CAP produced a significantly greater reduction in viable organisms when compared to HOCL (p ≤ 0.05) against all tested bacterial isolates. PG + CAP was highly effective against biofilms of all resistant bacterial isolates and is a promising option that merits further study for treating chronic wounds contaminated with bacterial biofilms.
- Open Access
- 24 September 2025
- Published by MDPI AG in Preprints.org
Elevated Antibacterial Activity with Decreased Cytotoxicity of a Polygalacturonic + Caprylic Acid Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model
Introduction: Natural, plant-based agents are alternatives to antibiotics and antiseptics in treating bacterially colonized wounds and potentially offer an antimicrobial activity without cytotoxicity. In this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to be more representative of the wound biofilm environment. We compared a common antiseptic wound care agent, hypochlorous acid (HOCl), with a combination of two plant-based agents; polygalacturonic acid (PG) and caprylic acid (CAP) for bacterial biofilm eradication and assessed their cytotoxicities towards fibroblast cells. Material and Methods: The efficacy PG+CAP ointment was compared to HOCl irrigant solution in biofilm eradication using the FGWB against clinical resistant bacterial isolates of MRSA, MDR Pseudomonas aeruginosa, CRE Escherichia coli, and Streptococcus pyogenes. Trypan blue exclusion and Alamar blue conversion assays were used for cytotoxicity assays. Results: PG+CAP produced a significantly greater reduction of viable organisms than HOCl for all tested bacterial isolates in the FGWB model (P≤ 0.05). Also, cytotoxicity tests showed that, PG+CAP was comparable to the non-antimicrobial negative control and was less cytotoxic than HOCl (P≤0.05). Conclusion: PG+CAP was highly effective against biofilms of highly resistant bacterial isolates in the FGWB model, and less cytotoxic than HOCl. PG+CAP merits further in vivo study.
- 24 September 2025
- Published by MDPI AG in Preprints.org
Open AccessElevated Antibacterial Activity with Decreased Cytotoxicity of a Polygalacturonic + Caprylic Acid Wound Ointment Compared with Hypochlorous Acid in a Three-Dimensional Wound Biofilm Model
Introduction: Natural, plant-based agents are alternatives to antibiotics and antiseptics in treating bacterially colonized wounds and potentially offer an antimicrobial activity without cytotoxicity. In this study, we used a three-dimensional fibrin-gel wound biofilm (FGWB) model to be more representative of the wound biofilm environment. We compared a common antiseptic wound care agent, hypochlorous acid (HOCl), with a combination of two plant-based agents; polygalacturonic acid (PG) and caprylic acid (CAP) for bacterial biofilm eradication and assessed their cytotoxicities towards fibroblast cells. Material and Methods: The efficacy PG+CAP ointment was compared to HOCl irrigant solution in biofilm eradication using the FGWB against clinical resistant bacterial isolates of MRSA, MDR Pseudomonas aeruginosa, CRE Escherichia coli, and Streptococcus pyogenes. Trypan blue exclusion and Alamar blue conversion assays were used for cytotoxicity assays. Results: PG+CAP produced a significantly greater reduction of viable organisms than HOCl for all tested bacterial isolates in the FGWB model (P≤ 0.05). Also, cytotoxicity tests showed that, PG+CAP was comparable to the non-antimicrobial negative control and was less cytotoxic than HOCl (P≤0.05). Conclusion: PG+CAP was highly effective against biofilms of highly resistant bacterial isolates in the FGWB model, and less cytotoxic than HOCl. PG+CAP merits further in vivo study.
- 25 April 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 161, 114-118
Comparative in-vitro antimicrobial activity of silver- and minocycline–rifampin–chlorhexidine-coated needle-free connectors
- 25 April 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 161, 114-118
Comparative in-vitro antimicrobial activity of silver- and minocycline–rifampin–chlorhexidine-coated needle-free connectors
- Open Access
- 24 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 178
The Antifungal Activity of a Polygalacturonic and Caprylic Acid Ointment in an In Vitro, Three-Dimensional Wound Biofilm Model
Candida colonization and biofilms are significant contributors to impaired wound healing. Consequently, improved treatments are needed to eradicate Candida biofilms in wounds. Wounds present complex biofilm extracellular matrix environments, with microbial cells frequently enmeshed in matrices comprising wound exudate macromolecular gels. We evaluated the ability of a polygalacturonic and caprylic acid (PG + CAP) ointment to eradicate Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. auris biofilms in a fibrin gel wound biofilm model of the complex wound biofilm environment. Hypochlorous acid (HOCl) is a disinfecting antimicrobial agent that is widely used as wound irrigant, and this was used as a comparator. A single treatment with PG + CAP reduced the number of viable organisms in the C. albicans and C. glabrata biofilms by over 5 log10, in the C. parapsilosis and C. auris biofilms by over 4 log10, and in the C. tropicalis biofilm by 3.85 log10. PG + CAP was superior (p < 0.01) to HOCl in eradicating all Candida species biofilms, except for C. auris, for which both treatments fully eradicated all viable organisms. The use of HOCl in Candida-colonized wounds should include consideration of the extracellular matrix load in the wound bed. PG + CAP warrants further study in wounds compromised by Candida biofilms.
- 24 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 178
Open AccessThe Antifungal Activity of a Polygalacturonic and Caprylic Acid Ointment in an In Vitro, Three-Dimensional Wound Biofilm Model
Candida colonization and biofilms are significant contributors to impaired wound healing. Consequently, improved treatments are needed to eradicate Candida biofilms in wounds. Wounds present complex biofilm extracellular matrix environments, with microbial cells frequently enmeshed in matrices comprising wound exudate macromolecular gels. We evaluated the ability of a polygalacturonic and caprylic acid (PG + CAP) ointment to eradicate Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. auris biofilms in a fibrin gel wound biofilm model of the complex wound biofilm environment. Hypochlorous acid (HOCl) is a disinfecting antimicrobial agent that is widely used as wound irrigant, and this was used as a comparator. A single treatment with PG + CAP reduced the number of viable organisms in the C. albicans and C. glabrata biofilms by over 5 log10, in the C. parapsilosis and C. auris biofilms by over 4 log10, and in the C. tropicalis biofilm by 3.85 log10. PG + CAP was superior (p < 0.01) to HOCl in eradicating all Candida species biofilms, except for C. auris, for which both treatments fully eradicated all viable organisms. The use of HOCl in Candida-colonized wounds should include consideration of the extracellular matrix load in the wound bed. PG + CAP warrants further study in wounds compromised by Candida biofilms.
- 5 November 2024
- Published by Elsevier in Journal of Medical Mycology
- Vol. 34 (4) , 101519
Eradication of Candida auris biofilm in vitro by a polygalacturonic and caprylic acid wound ointment
- 5 November 2024
- Published by Elsevier in Journal of Medical Mycology
- Vol. 34 (4) , 101519
Eradication of Candida auris biofilm in vitro by a polygalacturonic and caprylic acid wound ointment
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2123. Novel Antimicrobial Polycarbonate Coating for Intravenous Connectors
IV connectors are ubiquitous access junctions in vascular access circuits. Unlike vascular catheters and IV lines made from soft polymers, connectors are made from rigid polycarbonate (PC) to prevent deformation during manipulation. In accessing PC connectors (PCCs) for infusion, PCCs are vulnerable to becoming microbially contaminated. Here we report development of a novel antimicrobial polycarbonate coating for preventing microbial colonization of IV connectors. The FDA recently approved a new antimicrobial polyurethane catheter coating that comprised Minocycline (M), Rifampin (R), and Chlorhexidine (C). We spray-coated MRC onto PCCs as sequential laminate layers of M, R and C in PC or blend PC and polycarbonate-urethane copolymers. MRC coated PCCs were immersed in tubes filled with 50% serum + 50% saline to simulate elution of the coatings. After 7 days (typical interval of use prior to replacement of IV connectors), eluted connectors were exposed to challenge inocula of key CLABSI pathogen clinical isolates for 24 hours and the number of colonizing microbes were enumerated by sonication, serial dilution, plating and colony counting. Non-coated PCCs were positive controls. The absence of microbial colonization of the MRC IV connectors demonstrates the efficacy and durability of the novel MRC polycarbonate laminate coating. MRC coated connectors merit further testing in vitro and in vivo for their potential to prevent CLABSI. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2123. Novel Antimicrobial Polycarbonate Coating for Intravenous Connectors
IV connectors are ubiquitous access junctions in vascular access circuits. Unlike vascular catheters and IV lines made from soft polymers, connectors are made from rigid polycarbonate (PC) to prevent deformation during manipulation. In accessing PC connectors (PCCs) for infusion, PCCs are vulnerable to becoming microbially contaminated. Here we report development of a novel antimicrobial polycarbonate coating for preventing microbial colonization of IV connectors. The FDA recently approved a new antimicrobial polyurethane catheter coating that comprised Minocycline (M), Rifampin (R), and Chlorhexidine (C). We spray-coated MRC onto PCCs as sequential laminate layers of M, R and C in PC or blend PC and polycarbonate-urethane copolymers. MRC coated PCCs were immersed in tubes filled with 50% serum + 50% saline to simulate elution of the coatings. After 7 days (typical interval of use prior to replacement of IV connectors), eluted connectors were exposed to challenge inocula of key CLABSI pathogen clinical isolates for 24 hours and the number of colonizing microbes were enumerated by sonication, serial dilution, plating and colony counting. Non-coated PCCs were positive controls. The absence of microbial colonization of the MRC IV connectors demonstrates the efficacy and durability of the novel MRC polycarbonate laminate coating. MRC coated connectors merit further testing in vitro and in vivo for their potential to prevent CLABSI. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
Gram negative (GN) bacterial infections are on the rise in patients with cancer (PWC). There is an urgent need for new therapies to address the rise of infections caused by multidrug resistant (MDR) GN pathogens. Taniborbactam is a β-lactamase inhibitor in combination with cefepime may offer a potential treatment option for patients with serious GN bacterial infections. This study aimed to evaluate the in vitro activity of a novel combination of cefepime-taniborbactam and comparators against recent Gram-negative clinical isolates from PWC. Recent GN clinical isolates from PWC were tested against cefepime-taniborbactam and comparators. Clinical and laboratory Standards Institute (CLSI) approved broth microdilution method was used. Appropriate ATCC controls were included. MIC90, and percent of susceptibility calculations were made using FDA breakpoints when available. We tested 100 GN isolates and further testing is ongoing. Cefepime-taniborbactam and comparators antibiotics susceptibility percentage (S: %), and MIC90 are shown in the table below. Cefepime-taniborbactam demonstrated highly potent activity against all of tested Enterobacterales including extended spectrum Beta-lactamase (ESBL), and carbapenem-resistant Enterobacterales (CRE) as well as against P. aeruginosa and Stenotrophomonas maltophilia. At a provisional breakpoint of 16/4 mg/L, cefepime-taniborbactam showed highest activity against all tested isolates when compared to cefepime and other comparators, including activity against ESBL, CRE, MDR P. aeruginosa and S. maltophilia. Our data demonstrate that cefepime-taniborbactam has promising activity against clinically significant multidrug-resistant (MDR) GN bacterial pathogens isolated from PWC and it showed high activity compared to other commonly used broad spectrum antimicrobial agents. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
Gram negative (GN) bacterial infections are on the rise in patients with cancer (PWC). There is an urgent need for new therapies to address the rise of infections caused by multidrug resistant (MDR) GN pathogens. Taniborbactam is a β-lactamase inhibitor in combination with cefepime may offer a potential treatment option for patients with serious GN bacterial infections. This study aimed to evaluate the in vitro activity of a novel combination of cefepime-taniborbactam and comparators against recent Gram-negative clinical isolates from PWC. Recent GN clinical isolates from PWC were tested against cefepime-taniborbactam and comparators. Clinical and laboratory Standards Institute (CLSI) approved broth microdilution method was used. Appropriate ATCC controls were included. MIC90, and percent of susceptibility calculations were made using FDA breakpoints when available. We tested 100 GN isolates and further testing is ongoing. Cefepime-taniborbactam and comparators antibiotics susceptibility percentage (S: %), and MIC90 are shown in the table below. Cefepime-taniborbactam demonstrated highly potent activity against all of tested Enterobacterales including extended spectrum Beta-lactamase (ESBL), and carbapenem-resistant Enterobacterales (CRE) as well as against P. aeruginosa and Stenotrophomonas maltophilia. At a provisional breakpoint of 16/4 mg/L, cefepime-taniborbactam showed highest activity against all tested isolates when compared to cefepime and other comparators, including activity against ESBL, CRE, MDR P. aeruginosa and S. maltophilia. Our data demonstrate that cefepime-taniborbactam has promising activity against clinically significant multidrug-resistant (MDR) GN bacterial pathogens isolated from PWC and it showed high activity compared to other commonly used broad spectrum antimicrobial agents. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2124. Novel Polygalacturonic and Caprylic Acid (PG+CAP) Antimicrobial Wound Ointment Effectiveness in Eradicating C. auris Biofilms In Vitro
Candida auris (CA) is a multidrug-resistant fungal pathogen of increasing concern and has caused infection outbreaks in hospitals as a result of nosocomial transmission. CA has caused both invasive bloodstream and wound infections with significant morbidity and mortality. Recently, a novel polygalacturonic and caprylic acid (PG+CAP) antimicrobial wound ointment was highly effective in healing microbially contaminated chronic wounds in a pilot prospective randomized clinical trial when compared to MediHoney. In order to better combat CA wound infections, here we assessed the effectiveness of PG+CAP and MediHoney wound ointments in eradicating mature CA biofilms in vitro. A well-established biofilm eradication model was used to quantify antimicrobial efficacy. Forty-eight-hour biofilm of two different strains of CA (AR0381 and AR0382) were formed separately on silicone discs and then exposed to PG+CAP or MediHoney wound ointment for two hours. The silicone discs were sonicated in neutralizer, then serially diluted, plated and counted to enumerate viable colonies remaining following exposure to the ointments. Positive controls were discs that had no wound ointment treatment. Both ointments fully eradicated biofilm for CA strain AR0381. PG+CAP fully eradicated AR0382 biofilm (greater than 5-log reduction) but MediHoney achieved less than a 3-log reduction against AR0382. The difference between PG+CAP and MediHoney for AR0382 was significant (p = 0.02). These results suggest PG+CAP might be a promising ointment for use in treating CA wound infections and merits further study. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2124. Novel Polygalacturonic and Caprylic Acid (PG+CAP) Antimicrobial Wound Ointment Effectiveness in Eradicating C. auris Biofilms In Vitro
Candida auris (CA) is a multidrug-resistant fungal pathogen of increasing concern and has caused infection outbreaks in hospitals as a result of nosocomial transmission. CA has caused both invasive bloodstream and wound infections with significant morbidity and mortality. Recently, a novel polygalacturonic and caprylic acid (PG+CAP) antimicrobial wound ointment was highly effective in healing microbially contaminated chronic wounds in a pilot prospective randomized clinical trial when compared to MediHoney. In order to better combat CA wound infections, here we assessed the effectiveness of PG+CAP and MediHoney wound ointments in eradicating mature CA biofilms in vitro. A well-established biofilm eradication model was used to quantify antimicrobial efficacy. Forty-eight-hour biofilm of two different strains of CA (AR0381 and AR0382) were formed separately on silicone discs and then exposed to PG+CAP or MediHoney wound ointment for two hours. The silicone discs were sonicated in neutralizer, then serially diluted, plated and counted to enumerate viable colonies remaining following exposure to the ointments. Positive controls were discs that had no wound ointment treatment. Both ointments fully eradicated biofilm for CA strain AR0381. PG+CAP fully eradicated AR0382 biofilm (greater than 5-log reduction) but MediHoney achieved less than a 3-log reduction against AR0382. The difference between PG+CAP and MediHoney for AR0382 was significant (p = 0.02). These results suggest PG+CAP might be a promising ointment for use in treating CA wound infections and merits further study. Joel Rosenblatt, PhD, Novel Anti-Infective Technologies, LLC: Licensed Technology Issam I. Raad, Distinguished Professor, Novel Anti-Infective Technologies, LLC: Technology License
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Enhanced Biofilm Eradication and Reduced Cytotoxicity of a Novel Polygalacturonic and Caprylic Acid Wound Ointment Compared with Common Antiseptic Ointments
Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel combination that has been shown to eradicate biofilms. We developed a novel PG+CAP ointment and compared the biofilm eradication capability and cytotoxicity of PG+CAP with that of commercially available antiseptic wound ointments. We used a well‐established biofilm model to quantitatively assess the eradication of organisms following exposure to the wound ointments for 2 hours. PG+CAP ointment completely eradicated Candida albicans, multidrug‐resistant Pseudomonas aeruginosa, and methicillin‐resistant Staphylococcus aureus biofilms, whereas MediHoney, polyhexamethylene biguanide (PHMB), and benzalkonium chloride (BZK) ointments failed to eradicate all biofilms within 2 hours. We assessed cytotoxicity by exposing L‐929 fibroblasts to extracts of each ointment; Trypan blue exclusion was used to assess cell viability, and Alamar blue conversion was used to assess metabolic function. After exposure to PG+CAP and MediHoney, fibroblast viability was 96.23% and 95.23%, respectively (Trypan blue), and was comparable to untreated cells (98.77%). PHMB and BZK showed reduced viability (83.25% and 77.83%, respectively, p < 0.05). Metabolic activity results followed a similar pattern. Cytotoxicity of PG+CAP ointment towards erythrocytes was comparable to saline. PG+CAP ointment seems to be safe and can rapidly eradicate microbial biofilm; thus, PG+CAP ointment merits further in vivo testing as a potential antimicrobial wound ointment.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessEnhanced Biofilm Eradication and Reduced Cytotoxicity of a Novel Polygalacturonic and Caprylic Acid Wound Ointment Compared with Common Antiseptic Ointments
Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel combination that has been shown to eradicate biofilms. We developed a novel PG+CAP ointment and compared the biofilm eradication capability and cytotoxicity of PG+CAP with that of commercially available antiseptic wound ointments. We used a well‐established biofilm model to quantitatively assess the eradication of organisms following exposure to the wound ointments for 2 hours. PG+CAP ointment completely eradicated Candida albicans, multidrug‐resistant Pseudomonas aeruginosa, and methicillin‐resistant Staphylococcus aureus biofilms, whereas MediHoney, polyhexamethylene biguanide (PHMB), and benzalkonium chloride (BZK) ointments failed to eradicate all biofilms within 2 hours. We assessed cytotoxicity by exposing L‐929 fibroblasts to extracts of each ointment; Trypan blue exclusion was used to assess cell viability, and Alamar blue conversion was used to assess metabolic function. After exposure to PG+CAP and MediHoney, fibroblast viability was 96.23% and 95.23%, respectively (Trypan blue), and was comparable to untreated cells (98.77%). PHMB and BZK showed reduced viability (83.25% and 77.83%, respectively, p < 0.05). Metabolic activity results followed a similar pattern. Cytotoxicity of PG+CAP ointment towards erythrocytes was comparable to saline. PG+CAP ointment seems to be safe and can rapidly eradicate microbial biofilm; thus, PG+CAP ointment merits further in vivo testing as a potential antimicrobial wound ointment.